Anthony Colletta, ChairmanDr Colletta is an experienced financier, executive and director in the life sciences industry. Anthony was awarded a Doctorate from King’s College Hospital School of Medicine, and from 1984 through 1995 held a series of distinguished research positions, including that of Group Head at the Institute of Cancer Research and Royal Marsden Hospital in London, where he remains a lifetime honorary research fellow. In 1995, Dr Colletta was recruited to the post of Head of Healthcare Equity Research and Investment Banking at ABN AMRO, leading the healthcare group at ABN AMRO private equity. From 2000-2004, he served as Managing Director responsible for global healthcare equity research at Dresdner Bank in London, from 2004-2006 as CEO and Head of Global Healthcare Funds for Satellite Asset Management, and from 2006-2011 as Managing Partner at In Vivo Capital and Technikos Capital. Dr Colletta has managed more than 50 healthcare and life sciences investments and multi-hundred-million-pound portfolios. He currently acts as an angel investor and independent director and has sat on the board of more than 15 small-cap companies that have achieved successful exits.
Andrew Lynn, Chief Executive OfficerAndrew Lynn is an entrepreneur and executive with a focus on early-stage life-sciences and technology opportunities. Andrew founded the regenerative medical device company Orthomimetics Ltd, based on his PhD thesis at the University of Cambridge. He then led the company as CEO from incorporation to successful trade-sale exit. During his tenure at Orthomimetics, the company raised £7.5 million in venture capital and grant funding, established commercial-scale manufacturing capabilities and brought the flagship product through pilot clinical trials to market. In 2009, he led a process that culminated in the successful sale of the company. Dr Lynn subsequently led solid-state-lighting venture CamGaN Limited as CEO from the commencement of operations to a successful exit in 2012. His efforts have earned him recognition in Europe as an inaugural winner of a Science|Business Academic Enterprise Award and in the US as a member of Technology Review Magazine’s TR35 list of the world’s top young innovators, leaders and entrepreneurs.
Tuomas Knowles, Founder and Chief Scientific OfficerProfessor Knowles holds a personal Professorship in the Department of Chemistry at the University of Cambridge and is also a Fellow of St John’s College Cambridge. Tuomas received his PhD in Physics from the University of Cambridge, and has held positions in Engineering in Cambridge and Harvard University before returning to Cambridge as a University Lecturer in 2010, Reader in 2013 and then Professor in 2015. His current research interests are focused on using physical approaches to study the self-assembly of protein molecules both in the context of disease and for the synthesis of novel functional biomaterials. Professor Knowles has received a number of distinguished awards, most recently from the Royal Society of Chemistry, the Newman Foundation and the European Research Council. Professor Knowles has co-authored over 60 peer-reviewed scientific articles.
Vishal Gulati, Investor DirectorDr Vishal Gulati is a Venture Partner at DFJ Esprit and one of the Europe’s leading digital healthcare investors. He is a qualified physician and is Chairman of the Digital Health Forum. Over the last decade, Vishal has championed deals across areas including diagnostics, devices & biotech. In addition to his directorship at Fluidic Analytics, he is currently on the boards of Horizon Discovery PLC and EcoEos. His investments include Napo Pharmaceuticals, Glenmark, Renovo, Phagenesis and he has also held board positions at Psynova Neurotech, Bioscale and Enigma Diagnostics. Prior to joining DFJ Esprit, Vishal worked at Atlas Venture, The Wellcome Trust and Radiant Capital.
Bradley Hardiman, Investor DirectorBradley Hardiman is the Life Sciences Investment Manager at Cambridge Enterprise Seed Funds. Bradley started his career as a life scientist working for the world’s largest pharmaceutical companies. He then moved in to technology transfer and business incubation, commercialising university research. Bradley’s previous role was Head of Business Incubation at Design London, a partnership between Imperial College and the Royal College of Art. It was here that he gained experience of a wide range of industrial sectors including heavy manufacturing, fire suppression, electrical engineering and fashion. Bradley has a B.Sc. In Medical Biochemistry from Brunel University, a Research Master’s degree in Molecular Biochemistry from the University of Cambridge and an Executive MBA from Cass Business School. He is a Visiting Fellow at InnovationRCA, the commercialisation arm of the Royal College of Art.
Fluidic Analytics was formed in 2013 as a spin-out from the Department of Chemistry at the University of Cambridge.
Our roots stretch back to a group of scientists who were inspired by the roles that proteins play in the biological world, driven to understand more about how proteins behave and function, but frustrated by the lack of suitable tools for protein characterisation. So they decided to invent their own.
Our vision is that protein science will transform our understanding of how the biological world operates in real time. We believe that this transformation will be every bit as revolutionary as the way that advances in DNA sequencing have transformed our understanding of how the biological world operates over decades, lifetimes and generations. And we believe that Fluidic Analytics can help make this vision a reality by developing products that enable easier, faster, more convenient and more accurate protein characterisation, whether in the lab, at the bedside or in everyday life.